Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
134 stopped studies mapped to Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma and descendants · 83% state a reason
Over the 134 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT07388563 | Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma | Phase 1 | suspended | Feb 5, 2026 | National Cancer Institute (NCI) | New recruitment on hold for a protocol design amendment/modification. | Enrollment / accrual |
| NCT02702310 | Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed… | — | suspended | Mar 8, 2016 | Vanderbilt-Ingram Cancer Center | Treatment unavailable at facility | Other (stated, no rule matched) |
| NCT05377827 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of… | Phase 1 | suspended | May 17, 2022 | Washington University School of Medicine | Drugs/Equipment Unavailable | Other (stated, no rule matched) |
| NCT06470451 | Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL(FLASH2) | Phase 3 | terminated | Jun 24, 2024 | Soligenix | The Data Monitoring Committee conducted an interim analysis and recommended that the study be… | Efficacy / futility |
| NCT05414500 | Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides | Phase 1 | suspended | Jun 10, 2022 | University of Alabama at Birmingham | IRB audit | Other (stated, no rule matched) |
| NCT02943642 | Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With…(Resimmune®) | Phase 2 | withdrawn | Oct 25, 2016 | Virogen Biotechnology Inc. | This record is an earlier version (crossover design). After FDA-approved IND sponsor transfer to… | Other (stated, no rule matched) |
| NCT06870487 | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced… | Phase 1 | terminated | Mar 11, 2025 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT06692452 | Tazemetostat Plus CHOP in 1L T-cell Lymphoma | Phase 2 | withdrawn | Nov 18, 2024 | Eric Jacobsen, MD | Ipsen requested a temporary closure due to a safety concern. | Safety / toxicity |
| NCT03590574 | Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1… | Phase 1 / Phase 2 | terminated | Jul 18, 2018 | Autolus Limited | Only Phase I of the study was conducted. | Other (stated, no rule matched) |
| NCT06235281 | Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)(PLIGHT) | Early Phase 1 | suspended | Jan 31, 2024 | H. Lee Moffitt Cancer Center and Research Institute | Slow Accrual | Enrollment / accrual |
| NCT04362007 | A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma | Phase 1 / Phase 2 | terminated | Apr 24, 2020 | Otsuka Pharmaceutical Co., Ltd. | The study was terminated early due to Sponsor decision, the decision to terminate was not based on… | Safety / toxicity |
| NCT04425070 | A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy…(TOUCH) | Phase 1 / Phase 2 | terminated | Jun 11, 2020 | Antengene Corporation | Based on the adjustment of clinical research and development strategy，sponsor decided to terminate… | Sponsor / business decision |
| NCT05083208 | PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of… | Phase 1 | terminated | Oct 19, 2021 | Henan Cancer Hospital | The clinical development of parsaclisib was stopped by it's manufacturer. | Drug supply |
| NCT04541017 | Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual… | Phase 1 / Phase 2 | terminated | Sep 9, 2020 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT05883449 | Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL(LuminICE-203) | Phase 2 | terminated | Jun 1, 2023 | Affimed GmbH | Due to sponsor decision | Sponsor / business decision |
| NCT05879458 | Ritlecitinib in CTCL | Phase 2 | terminated | May 30, 2023 | Icahn School of Medicine at Mount Sinai | No significant improvement in disease as graded by our assessments. | Other (stated, no rule matched) |
| NCT05538988 | BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd…(BIOSELECT) | Phase 1 / Phase 2 | withdrawn | Sep 14, 2022 | AHS Cancer Control Alberta | Contractual Issues | Other (stated, no rule matched) |
| NCT05106192 | Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel… | N/A | withdrawn | Nov 3, 2021 | Case Comprehensive Cancer Center | Study closed prior to enrollment of first participant | Enrollment / accrual |
| NCT03432741 | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With… | Phase 1 | terminated | Feb 14, 2018 | Mayo Clinic | funding - sponsor filing Chapter 11 bankruptcy | Funding |
| NCT02548468 | Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in… | Phase 1 | withdrawn | Sep 14, 2015 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT03288818 | Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel… | Phase 2 | withdrawn | Sep 20, 2017 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Funding discontinued | Funding |
| NCT06941688 | Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for… | Phase 2 | terminated | Apr 24, 2025 | Seoul National University Hospital | slow recruitment | Enrollment / accrual |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Phase 1 | terminated | Feb 5, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04676087 | Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or… | Phase 1 / Phase 2 | terminated | Dec 19, 2020 | Emory University | Lack of funding | Funding |
| NCT05105412 | Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas | Phase 1 / Phase 2 | terminated | Nov 3, 2021 | National Health Research Institutes, Taiwan | The resolution of DSMB | Other (stated, no rule matched) |
| NCT03789864 | Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis…(BDI) | N/A | terminated | Dec 31, 2018 | Indiana University | Lack of accrual in a timely fashion | Enrollment / accrual |
| NCT04548700 | Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and… | Phase 1 | terminated | Sep 14, 2020 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | The sponsor has adjusted its R\&D strategy. | Sponsor / business decision |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | Phase 1 | terminated | Jan 16, 2013 | Stanford University | Planned Future Study | Other (stated, no rule matched) |
| NCT05321940 | Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive… | Phase 1 | withdrawn | Apr 11, 2022 | Juan C. Ramos, MD | Investigator decision | Investigator |
| NCT04828174 | Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies | Phase 1 | suspended | Apr 1, 2021 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | The trial was suspended due to the inability to enroll qualified participants | Enrollment / accrual |
| NCT05138458 | A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL(IMAGINE) | Phase 1 / Phase 2 | suspended | Dec 1, 2021 | Myeloid Therapeutics | Temporary operational pause; no safety concerns. | Safety / toxicity |
| NCT03947255 | A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma… | Phase 2 | terminated | May 13, 2019 | Seagen Inc. | Study stopped early due to low patient accrual. | Enrollment / accrual |
| NCT04795869 | Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral… | Phase 2 | withdrawn | Mar 12, 2021 | Northwestern University | Study inactivated due to zero accruals | Enrollment / accrual |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant… | Phase 2 | terminated | Jan 8, 2010 | University of Nebraska | Study was closed to accrual for safety related to the frequency of BK infections. | Safety / toxicity |
| NCT03272633 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients… | Early Phase 1 | terminated | Sep 5, 2017 | Rutgers, The State University of New Jersey | Lack of enrollment | Enrollment / accrual |
| NCT01378871 | A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T… | Phase 2 | terminated | Jun 23, 2011 | Amit Verma | IND withdrawn | Other (stated, no rule matched) |
| NCT02440685 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid… | Phase 1 / Phase 2 | terminated | May 12, 2015 | Asana BioSciences | Business decision | Sponsor / business decision |
| NCT01579318 | Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma(CTCL) | Phase 2 | terminated | Apr 17, 2012 | OncoSec Medical Incorporated | Due to company resource constraints | Sponsor / business decision |
| NCT03999658 | A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected… | Phase 2 | withdrawn | Jun 27, 2019 | Sorrento Therapeutics, Inc. | Sorrento Therapeutics filed for chapter 11 bankruptcy. | Other (stated, no rule matched) |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory… | Phase 1 | terminated | Sep 7, 2016 | Pfizer | not stated | Not stated |
| NCT05513612 | Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies | Phase 1 | withdrawn | Aug 24, 2022 | Shanghai Pudong Hospital | The study is not initiated and we want it to be withdrawn. | Other (stated, no rule matched) |
| NCT04021082 | CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory… | Phase 2 / Phase 3 | withdrawn | Jul 16, 2019 | Portola Pharmaceuticals | Sponsor decision to not initiate the trial | Sponsor / business decision |
| NCT02314247 | Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell… | Phase 2 | terminated | Dec 11, 2014 | Karyopharm Therapeutics Inc | Due to enrollment challenges | Enrollment / accrual |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic… | Phase 2 | terminated | Dec 9, 2009 | Fred Hutchinson Cancer Center | The study experienced lower accrual rates after the onset of COVID. Upon review of the collected… | COVID-19 / pandemic |
| NCT01712659 | Ruxolitinib for Adult T-Cell Leukemia | Phase 1 / Phase 2 | terminated | Oct 23, 2012 | National Cancer Institute (NCI) | The adult T-cell leukemia (ATL) research program was terminated after the death of the T-cell… | Investigator |
| NCT04639843 | Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell… | Phase 1 | withdrawn | Nov 23, 2020 | National Cancer Institute (NCI) | Safety issues with PI3 kinase inhibitors | Safety / toxicity |
| NCT02811783 | Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of… | Phase 3 | terminated | Jun 23, 2016 | Elorac, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04444141 | A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell… | Phase 1 / Phase 2 | terminated | Jun 23, 2020 | Akeso | Due to difficuty of erollment and consideration of clinical guideline,The sponsor decided to stop… | Sponsor / business decision |
| NCT05239910 | Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front… | Phase 2 | withdrawn | Feb 15, 2022 | Rhizen Pharmaceuticals SA | Change in development plan | Other (stated, no rule matched) |
| NCT02572453 | Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL | Phase 2 | terminated | Oct 9, 2015 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Aug 26, 2026source: clinicaltrials